Frank Dolan

An illustration of a happy person standing on a scale, showing a significant weight loss achievement, with CT-996 molecule structures and icons for obesity and type 2 diabetes floating around them.

CT-996 Shows Notable Weight Reduction in Obese Individuals with Type 2 Diabetes

Frank Dolan July 18, 2024

An illustrated scene showing a team of scientists in a futuristic lab joyously discovering a breakthrough treatment for acute myeloid leukemia, with the FDA Fast Track Designation certificate displayed prominently in the foreground.

FDA Accelerates Review of Sumitomo Pharma’s New Therapy for Patients with Relapse or Treatment-Resistant Acute Myeloid Leukemia

Frank Dolan July 15, 2024

An illustration of a futuristic digital library with glowing books and holographic data charts, symbolizing registries of real-world evidence (RWE) being used to meet regulatory standards in healthcare.

Achieving Regulatory Standards: Using Registries as a Source of Regulatory-Quality Real-World Evidence

Frank Dolan July 11, 2024

A futuristic pharmacy covered in snow illustrating the impact of cold weather on asthma, next to a glowing billboard advertising the new FDA approved Alzheimer's drug, symbolizing a breakthrough in treatment, surrounded by a cityscape indicating progress in medical science.

Pharma Update July 4, 2024: Asthma Symptoms Could Intensify with Lower Temperatures, FDA Clears New Alzheimer’s Medication Ushering In Advanced Treatment Phase & Beyond.

Frank Dolan July 4, 2024

An illustration of a bright, hopeful sunrise over a scenic memory lane, symbolizing hope and rejuvenation, with a visible pill bottle labeled 'Kisunla' at the forefront, subtly implying the dawn of a new era in Alzheimer’s treatment.

FDA Greenlights Kisunla by Lilly for Early Symptomatic Alzheimer’s Disease Treatment.

Frank Dolan July 2, 2024

An impactful illustration showing a symbolic vial of Shorla Oncology's Tepylute with graceful elements representing breast and ovarian cancer treatment, encased in a hopeful, healing light.

FDA Greenlights Shorla Oncology’s Tepylute, a Premix Formulation for Breast and Ovarian Cancer Treatment.

Frank Dolan July 1, 2024

An informative and vibrant digital illustration showing a diverse panel of experts from the CDC’s Advisory Committee in discussion, with a large, visible display in the background showcasing the Vaxelis vaccine bottle. The foreground should feature a map of the United States highlighted with Alaska and American Indian territories, and illustrations of protected and healthy infants of American Indian and Alaska Native heritage, surrounded by symbolic representations of Hemophilus influenzae type B bacteria being shielded away.

CDC’s Advisory Panel Endorses Vaxelis With Full Agreement to Protect Against Invasive Hemophilus Influenzae Type B Among Native American and Alaska Native Infants

Frank Dolan June 28, 2024

FDA Sends Comprehensive Response Letter to Merck and Daiichi Sankyo Regarding Patritumab Deruxtecan for Advanced, Metastatic EGFR-Mutated Non-Small Cell Lung Cancer.

Frank Dolan June 27, 2024

Detailed illustration of a futuristic Novo Nordisk pharmaceutical manufacturing plant sprawling across a lush American landscape, with construction crews actively expanding the facility under a bright blue sky.

Novo Nordisk Commits $4.1 Billion to Enhance Production Facilities in the US

Frank Dolan June 25, 2024

An imaginative animation-style illustration showcasing a group of energetic children joyfully playing outdoors in the sunlight, symbolizing newfound wakefulness, with colorful pills labeled 'Wakix' gently floating down from a clear sky like leaves, while a subtle emblem of the FDA approval seal gleams in the corner.

FDA Gives Green Light to Wakix by Harmony Biosciences for Treating Overwhelming Daytime Sleepiness in Children with Narcolepsy

Frank Dolan June 24, 2024

An artistic visualization of futuristic cityscapes with holographic data charts overlayed, showcasing the evolution of society's trends from the present into the future.

Looking Beyond the Data: Projecting Current Trends into the Future

Frank Dolan June 20, 2024

An illustrated medical infographic detailing the mechanism of action of Amgen’s Blincyto in treating CD19-Positive Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia, including a depiction of B-cells and the Philadelphia chromosome.

FDA Grants Approval for Amgen’s Blincyto for the Treatment of CD19-Positive Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia.

Frank Dolan June 17, 2024

An illustration of a diverse group of professionals standing in front of a futuristic biopharma laboratory, with the leader pointing towards a glowing, innovative medicine vial, symbolizing progress and guidance through change.

Leadership in Biopharmaceuticals During Periods of Change.

Frank Dolan June 13, 2024

Digital illustration of a serene scientific breakthrough moment representing Sarclisa infusion in progress, with symbolic imagery of clocks or hourglasses turning backwards and multiple myeloma cells diminishing in the background, highlighting improved progression-free survival for patients. Include a diverse group of hopeful patients watching the process around a futuristic medical device in a bright, modern treatment room setting.

Sarclisa Combo Enhances Survival without Disease Progression in Newly Diagnosed Multiple Myeloma Patients Unfit for Transplant.

Frank Dolan June 4, 2024

Detailed infographic comparing survival statistics of limited-stage small cell lung cancer patients treated with Imfinzi versus standard treatment, presented on a medical conference backdrop.

Phase III Study Results Revealed at ASCO Demonstrate Imfinzi Enhances Survival in Limited-Stage Small Cell Lung Cancer.

Frank Dolan June 3, 2024

An illustration of interconnected healthcare professionals and patients within the futuristic Veradigm Network ecosystem, showcasing improved patient outcomes and efficiencies in value-based care.

Comprehending the Influence of the Veradigm Network on Delivering Healthcare Based on Value.

Frank Dolan June 1, 2024

An illustrated digital poster showcasing a magnified view of a human cell being targeted by Scemblix medication, with a background of glowing Philadelphia Chromosome-positive Chronic Myeloid Leukemia symbols transitioning to a healthy cell state, emphasizing major molecular response improvement.

Scemblix Demonstrates Enhanced Major Molecular Response in Treatment of Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

Frank Dolan May 31, 2024

A futuristic laboratory with scientists unveiling Onyda XR, a once-daily, extended-release oral suspension for ADHD treatment, surrounded by holograms of the brain and time-release graphics.

FDA Clears Tris Pharma’s Onyda XR for ADHD: A Daily, Long-Acting Oral Liquid Medication

Frank Dolan May 30, 2024

FDA Accelerates Review of Keytruda Combo as Initial Therapy for Inoperable Advanced or Metastatic Malignant Pleural Mesothelioma.

Frank Dolan May 29, 2024

An artistic representation of the merger between Johnson & Johnson and Numab, symbolized by two entities shaking hands made of intertwined antibodies, set against the backdrop of a serene landscape healing from atopic dermatitis.

Johnson & Johnson Secures Numab’s Experimental Antibody for Atopic Dermatitis Treatment.

Frank Dolan May 28, 2024

Stay up to date on the latest news

By pressing the Subscribe button, you confirm that you have read our Privacy Policy.

Iovance Biotherapeutics Stock Plummets 44%: What Investors Need to Know About 2025 Projections

Iovance Biotherapeutics Stock Plummets 44%: What Investors Need to Know About 2025 Projections

Insilico Medicine's Third Attempt at an IPO: Aiming Big in Hong Kong's Booming Biotech Market

Insilico Medicine’s Third Attempt at an IPO: Aiming Big in Hong Kong’s Booming Biotech Market

Biotech Sector Faces Major Workforce Cuts: Layoffs Surge as Firms Navigate Market Turbulence

Biotech Sector Faces Major Workforce Cuts: Layoffs Surge as Firms Navigate Market Turbulence

Email Us

info at arsenal-advisors.com

Headquarters

Cambridge, MA USA